174,536 Shares in DBV TECHNOLOGIE/S (DBVT) Acquired by Premier Asset Management LLC

Premier Asset Management LLC acquired a new position in shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 174,536 shares of the company’s stock, valued at approximately $1,121,000. Premier Asset Management LLC owned approximately 0.29% of DBV TECHNOLOGIE/S as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in DBV TECHNOLOGIE/S by 0.9% during the 3rd quarter. BlackRock Inc. now owns 312,261 shares of the company’s stock worth $7,014,000 after buying an additional 2,741 shares in the last quarter. Exane Asset Management raised its position in shares of DBV TECHNOLOGIE/S by 30.0% during the 3rd quarter. Exane Asset Management now owns 65,000 shares of the company’s stock valued at $1,460,000 after acquiring an additional 15,000 shares during the last quarter. FMR LLC raised its position in shares of DBV TECHNOLOGIE/S by 1.4% during the 3rd quarter. FMR LLC now owns 1,325,676 shares of the company’s stock valued at $29,775,000 after acquiring an additional 18,744 shares during the last quarter. Bailard Inc. raised its position in shares of DBV TECHNOLOGIE/S by 57.4% during the 3rd quarter. Bailard Inc. now owns 74,000 shares of the company’s stock valued at $1,662,000 after acquiring an additional 27,000 shares during the last quarter. Finally, OLD Mission Capital LLC increased its position in shares of DBV TECHNOLOGIE/S by 1,278.6% in the 4th quarter. OLD Mission Capital LLC now owns 143,338 shares of the company’s stock valued at $920,000 after buying an additional 132,941 shares in the last quarter. 44.09% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:DBVT traded down $0.21 during mid-day trading on Monday, reaching $9.04. The stock had a trading volume of 187,412 shares, compared to its average volume of 379,979. The stock has a market capitalization of $549.82 million, a price-to-earnings ratio of -2.68 and a beta of 1.97. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.34 and a quick ratio of 3.30. DBV TECHNOLOGIE/S has a 12 month low of $3.60 and a 12 month high of $25.77.

A number of equities analysts have issued reports on the company. Zacks Investment Research cut DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a report on Friday. BidaskClub upgraded shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research note on Friday, April 5th. Stifel Nicolaus reiterated a “hold” rating and issued a $10.00 target price on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. JMP Securities reiterated a “buy” rating and issued a $20.00 target price on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Finally, ValuEngine downgraded shares of DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. DBV TECHNOLOGIE/S currently has an average rating of “Hold” and an average price target of $14.78.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/15/premier-asset-management-llc-invests-1-12-million-in-dbv-technologie-s-dbvt.html.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Recommended Story: Stock Selection – What is cash flow?

Institutional Ownership by Quarter for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.